“Given the long-term success of Humira, which can cost patients up to $84,000 a year, initial uptake of the biosimilars may be limited, said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors.”
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.
Two years ago, in the aftermath of the 2020 Congressional election, I wrote: Democrats will retain the majority and the Speaker of the House—second in line to the presidency—will again be Nancy Pelosi.
Almost three years after COVID-19 changed the world, pandemic fatigue is in full swing.
